



Antibody Constructs

Guest Editors:

Dr. Satoshi Ohtake

Pharmaceutical R&D,
BioTherapeutics Pharmaceutical
Sciences, Pfizer Inc., 700
Chesterfield Parkway West,
Chesterfield, MO 63017, USA

Dr. Tsutomu Arakawa

Alliance Protein Laboratories,
6042 Cornerstone Ct West, Suite
A1, San Diego, CA 92121, USA

Deadline for manuscript
submissions:
closed (30 November 2014)

Message from the Guest Editors

Dear Colleagues,

Antibody fragments are under development as a next generation antibody therapeutic that takes advantage of their smaller sizes in comparison to a full antibody. They have unique structural characteristics, and hence challenges, which may differ from those of full antibodies in regard to production, purification/refolding, and formulation. The current Special Issue welcomes contributions from experts in the field that address and review the current state-of-the-art technology and developments in the field of antibody fragments.

Dr. Satoshi Ohtake

Dr. Tsutomu Arakawa

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: CiteScore - Q2 (*Drug Discovery*)

Contact Us

Antibodies Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
X@Antibodies_MDPI